Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

Emmanuel S. Antonarakis, MBBCh
Published: Friday, Feb 27, 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

In a previous study, it was seen that the presence of AR-V7 was associated with little or no response to the agents abiraterone and enzalutamide.

In this analysis, researchers looked at the correlation of the presence of AR-V7 and response to taxane chemotherapies. Antonarakis says that AR-V7 did not cause primary resistance to taxane chemotherapies. If a patient is diagnosed with AR-V7 in their tumors, they may not respond to abiraterone or enzalutamide, but he has a decent chance of responding to chemotherapy.

<<< View more from the 2015 GU Cancer Symposium

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

In a previous study, it was seen that the presence of AR-V7 was associated with little or no response to the agents abiraterone and enzalutamide.

In this analysis, researchers looked at the correlation of the presence of AR-V7 and response to taxane chemotherapies. Antonarakis says that AR-V7 did not cause primary resistance to taxane chemotherapies. If a patient is diagnosed with AR-V7 in their tumors, they may not respond to abiraterone or enzalutamide, but he has a decent chance of responding to chemotherapy.

<<< View more from the 2015 GU Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x